摘要
目的对治疗特应性皮炎的选择性Janus激酶抑制剂进行量化评估,为临床合理用药方案决策提供科学的依据。方法根据《中国医疗机构药品评价与遴选快速指南(第二版)》,从药学特性、有效性、安全性、经济性与其他属性五个方面对乌帕替尼和阿布昔替尼进行综合评价并量化评估。结果乌帕替尼与阿布昔替尼的总分分别为80.5分和80.2分。乌帕替尼与阿布昔替尼在瘙痒缓解及皮损清除方面疗效确切,但在联合外用糖皮质激素等药物时,阿布昔替尼疗效提高幅度优于乌帕替尼。乌帕替尼在适用人群方面较阿布昔替尼范围更广,而阿布昔替尼血液系统不良反应发生率低于乌帕替尼。对于医疗机构药品遴选,两者均可推荐入选。结论阿布昔替尼适用于追求迅速见效、建立信心的患者,以及需要根据病情灵活调整治疗方案的患者。对于12岁以上青少年、严重肾功能不全或合并类风湿关节炎、溃疡性结肠炎等疾病的患者优选乌帕替尼。
AIM To quantitative evaluate of selective Janus kinase inhibitors in treatment of atopic dermatitis,and provide scientific basis for drug selection and clinical rational drug use.METHODS According to the Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition),a comprehensive evaluation of upadacitinib and abrocitinib was conducted from five aspects of pharmaceutical characteristics,efficacy,safety,economy,and other attributes,and scores were assigned.RESULTS The total scores of upadacitinib and abrocitinib were 80.5 and 80.2 respectively.Upadacitinib and abrocitinib had definite therapeutic effects in terms of itching relief,and skin lesion clearance.But when combined with topical corticosteroids and other drugs,the improvement in efficacy of abrocitinib was better than that of upadacitinib.Upadacitinib had a wider range of applicability compared to abrocitinib,but the incidence of adverse reactions in the blood system of abrocitinib was lower than that of upadacitinib.Upadacitinib and abrocitinib were recommended for admission.CONCLUSION Abrocitinib is suitable for patients who seek quick results and build confidence,as well as those who need to flexibly adjust treatment plans based on their condition.Upadacitinib is preferred for adolescents over 12 years old,patients with severe renal insufficiency,or concomitant diseases such as rheumatoid arthritis and ulcerative colitis.
作者
赵越
杨浩天
薛朝军
李宵
鞠晓宇
赵倩
董占军
ZHAO Yue;YANG Hao-tian;XUE Chao-jun;LI Xiao;JU Xiao-yu;ZHAO Qian;DONG Zhan-jun(Department of Pharmacy,Hebei General Hospital,Shijiazhuang HEBEI 050057,China;Department of Pharmacy,Hebei Provincial Hospital of Chinese Medicine,Shijiazhuang HEBEI 050011,China;Hebei Key Laboratory of Clinical Pharmacy,Shijiazhuang HEBEI 050051,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2024年第5期374-379,共6页
Chinese Journal of New Drugs and Clinical Remedies
基金
河北省自然科学基金(H2020307043)
河北省医学科学研究课题(20240488)。
作者简介
赵越,男,主管药师,硕士,主要从事药品循证评价的研究,E-mail:zhaoyue900303@163.com。;董占军,男,主任药师,硕士,主要从事医院药事管理的研究,E-mail:13313213656@126.com。
